We tested this hypothesis by evaluating the killing activity of CD123-IgG1+ further with two standard AML cell lines, MOLM-13 and THP-1, which express CD123 at similar levels but differ in their expression of FcγRs (Fig. 1c). This evidence concerns the gene IL3RA and acute myeloid leukemia.